NCT03130439: Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

NCT03130439
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: Rb+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Either the primary tumor and/or the metastatic tumor must have retinoblastoma protein positivity (Rb+) which is defined as having greater than 50% of tumor cells staining positive for Rb
Exclusions: Patients with untreated symptomatic brain metastases that require therapy to control symptoms- see trial for details
https://ClinicalTrials.gov/show/NCT03130439

Comments are closed.

Up ↑